Table 4 Studies using intrasinus thrombolysis in the treatment of cerebral venous sinus thrombosis.
From: Factors influencing therapy choice and clinical outcome in cerebral venous sinus thrombosis
Authors | Number of patients | Type and dose of IST | Combination with MT | Outcome | Pre-treatment ICH | Worsening of ICH | |
|---|---|---|---|---|---|---|---|
Recanalization | mRS | ||||||
Kumar et al. (2010) | 19 | Urokinase: bolus 100,000 IU, continued by 100,000 IU/h, max. 600,000 IU | None | Complete: 5 Partial: 7 No: 7 | 0–2: 15 3–4: 0 5–6: 4 | 6/19 (32%) | 2/6 (33%) |
Guo et al. (2012) | 37 | Urokinase: 1,000,000 IU daily, 5–7 days | None | Complete: 30 Partial: 5 No: 2 | 0–2: 34 3–4: 1 5–6: 2 | 23/37 (62%) | 2/23 (9%) |
Mohammadian et al. (2012) | 26 | rtPA: total 30 mg in 30 min | None | complete: 25 partial: 0 no: 1 | 0–2: 25 3–4: 1 5–6: 0 | not available | |
Li et al. (2013) | 52 | Urokinase: total from 100,000 to 1,500,000 IU (240,000 IU/h) | All | complete: 45 partial: 3 no: 4 | 0–2: 40 3–4: 6 5–6: 6 | 29/52 (56%) | 4/29 (14%) |
Garge et al. (2014) | 10 | Urokinase: bolus 100,000 IU, continued by 60,000 IU/h, 10–18 h | None | Complete or partial: 10 No: 0 | 0–2: 9 3–4: 0 5–6: 1 | 10/10 (100%) | 1/10 (10%) |
Zhen et al. (2015) | 8 | rtPA: 20 mg daily, 4–6 days | All | Complete: 5 Partial: 2 No: 1 | 0–2: 7 3–4: 0 5–6: 1 | 2/8 (25%) | 0/2 (0%) |
Karanam et al. (2016) | 29 | rtPA: bolus 2 mg, continued by 1 mg/h, 11–16 h | None | Complete or partial: 29 No: 0 | 0–2: 27 3–4: 1 5–6: 1 | 29/29 (100%) | 0/29 (0%) |
Mathukumalli et al. (2016) | 24 | Urokinase (8 patients): bolus 100,000 IU, continued by 70–80,000IU/h, max. 3 days rtPA (16 patients): bolus 10 mg, continued by 1 mg/h, max. 3 days | None | Complete: 4 Partial: 18 No: 2 | 0–2: 10 3–4: 8 5–6: 6 | 14/24 (58%) | 0/14 (0%) |
Guo et al. (2019) | 156 | Urokinase: 1,000,000 IU daily, 5–7 days | None | Complete: 112 Partial: 28 No: 16 | 0–2: 120 3–4: 25 5–6: 11 | 17/156 (11%) | 3/17 (18%) |
